| Name | Title | Contact Details |
|---|
Austen Riggs Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in West Stockbridge, MA. To find more information about Austen Riggs Center, please visit www.austenriggs.net
F45 Training is a dynamic and ever-evolving leader in innovation across the health and fitness industry. Always pioneering, F45’s training methods set the benchmark in fitness and functional training, delivering results for clients every day. T...
We specialize in full-service senior living communities that offer an enriched lifestyle drawn from thoughtful details. When Andrew Kohlberg, our founder and president, purchased Kisco`s first retirement community in 1990, two thoughts emerged as the driving force: If my parents were to live in a retirement community, what would I want it to be like? And how would I want them to be treated? From these simple concepts, Kisco`s philosophy was shaped. We created our Principles, Values and Beliefs based on integrity, dignity and compassion. This belief system balances the needs of our residents, our employees – whom we regard as associates – and our business partners. Today our organization is nationwide, but we maintain a personal approach. We continuously reevaluate and refine our methods. We treat people with kindness and respect. We work to create environments that are inviting to residents, their families, and friends. We listen. At Kisco Senior Living, we aren`t aiming to be the biggest. We are aiming to be the best.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.